Development of affinity microparticles for extracorporeal blood purification based on crystalline bacterial cell surface proteins

被引:18
作者
Weber, V [1 ]
Weigert, S
Sára, M
Sleytr, UB
Falkenhagen, D
机构
[1] Donau Univ Krems, Ctr Biomed Technol, Christian Doppler Lab Specif Adsorpt Technol Med, Krems, Austria
[2] Univ Agr Sci, Ctr Ultrastruct Res, Vienna, Austria
[3] Univ Agr Sci, Ludwig Boltzmann Inst Mol Nanotechnol, Vienna, Austria
来源
THERAPEUTIC APHERESIS | 2001年 / 5卷 / 05期
关键词
adsorption; microparticles; immunoglobulins; blood purification; biocompatibility;
D O I
10.1046/j.1526-0968.2001.00354.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this article, the development of specific adsorbents for extracorporeal blood purification are described. Affinity microparticles were prepared by linking Protein A to crystalline cell surface layers (S-layers) from Thermoanaerobacter thermohydrosulfuricus 1111-69. Slayers were used in the form of cell wall fragments obtained by breaking whole cells by ultrasonification, resulting in cup-shaped structures (average size 0.5 x 1mum) completely covered with S-layer protein. Protein A was covalently bound to carboxylic acid groups, of the S-layer protein after activation with 1-ethyl-3,3'(dimethylamino)propylcarbodiimide. In batch adsorption experiments with fresh frozen human plasma, the resulting S-layer based affinity microparticles showed a high adsorption capacity for IgG (40 mg IgG were bound per g wet pellet of S-layer based affinity microparticles). Fractions eluted from the microparticles were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. They contained only IgG demonstrating that adsorption was specific. In biocompatibility tests, preparations of the S-layer microparticles showed no low-density lipoprotein-reactivity, no cytotoxicity, and no cytokine inducing activity.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 18 条
[1]   Immune modulation associated with extracorporeal immunoadsorption treatments utilizing protein A silica columns [J].
Balint, JP .
ARTIFICIAL ORGANS, 1996, 20 (08) :906-913
[2]   Current status in extracorporeal immunomodulation: Immune disorders [J].
Bosch, T .
ARTIFICIAL ORGANS, 1996, 20 (08) :902-905
[3]  
Caldwell J, 1999, J RHEUMATOL, V26, P1657
[4]  
FALKENHAGEN D, Patent No. 9504559
[5]  
Felson DT, 1999, ARTHRITIS RHEUM-US, V42, P2153, DOI 10.1002/1529-0131(199910)42:10<2153::AID-ANR16>3.0.CO
[6]  
2-W
[7]   Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus [J].
Gaubitz, M ;
Seidel, M ;
Kummer, S ;
Schotte, H ;
Perniok, A ;
Domschke, W ;
Schneider, M .
JOURNAL OF AUTOIMMUNITY, 1998, 11 (05) :495-501
[8]  
HERMANSON GT, 1992, IMMOBILIZED FINITY L, P5
[9]  
KNOBL P, 1995, THROMB HAEMOSTASIS, V74, P1035
[10]   Two-dimensional paracrystalline glycoprotein S-layers as a novel matrix for the immobilization of human IgG and their use as microparticles in immunoassays [J].
Kupcu, S ;
Sleytr, UB ;
Sara, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 196 (01) :73-84